The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia

In β-thalassemia, ineffective erythropoiesis leads to anemia and systemic iron overload. The management of iron overload by chelation therapy is a standard of care. However, iron chelation does not improve the ineffective erythropoiesis. We recently showed that the oral ferroportin inhibitor VIT-276...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyffenegger, Naja, Flace, Anna, Doucerain, Cédric, Dürrenberger, Franz, Manolova, Vania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830167/
https://www.ncbi.nlm.nih.gov/pubmed/33467196
http://dx.doi.org/10.3390/ijms22020873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830167/
https://www.ncbi.nlm.nih.gov/pubmed/33467196
http://dx.doi.org/10.3390/ijms22020873

Ejemplares similares